Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$198.86 USD

198.86
4,683,324

+2.56 (1.30%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $198.55 -0.31 (-0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Zacks Equity Research

Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit

by Zacks Equity Research

Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.

    Zacks Equity Research

    AbbVie's Imbruvica Fails in Phase III Blood Cancer Study

    by Zacks Equity Research

    AbbVie's (ABBV) Imbruvica fails to meet the primary endpoint in a phase III study evaluating the drug in patients with DLBCL, a rare blood cancer, who have received no prior treatment.

      Zacks Equity Research

      J&J (JNJ) to Set Pharma Q2 Earnings in Motion: What's Up?

      by Zacks Equity Research

      The positive trend seen in J&J's (JNJ) pharma segment sales in the past three quarters is likely to continue in Q2.

        Zacks Equity Research

        The Zacks Analyst Blog Highlights: Apache, Continental Resources, KMG Chemicals, ZAGG and AbbVie

        by Zacks Equity Research

        The Zacks Analyst Blog Highlights: Apache, Continental Resources, KMG Chemicals, ZAGG and AbbVie

          Tirthankar Chakraborty headshot

          Celebrate Trump's 2nd Year in Office With These 5 Winners

          by Tirthankar Chakraborty

          There's always a 67% chance that the U.S. stock market will scale north during the second year of presidential terms.

            Madhu Goel headshot

            3 Buy-Rated Large Cap Pharma Stocks to Boost Health in July

            by Madhu Goel

            We take a look at the three large cap pharma stocks that might be best bargains for the month of July.

              Zacks Equity Research

              Bristol-Myers' Sprycel Gets EC Approval for Label Expansion

              by Zacks Equity Research

              Bristol-Myers (BMY) receives EC approval for the label expansion of Sprycel for the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in patients aged one to 18 years.

                Zacks Equity Research

                Here's Why AbbVie Stock is Good for Your Portfolio's Health

                by Zacks Equity Research

                Here are six reasons why investing in AbbVie (ABBV) stock is a good decision now.

                  Zacks Equity Research

                  Is Pfizer's Price Hike an Effect of Drug Policy on Sector?

                  by Zacks Equity Research

                  Pfizer (PFE) reportedly raises prices of almost 100 drugs. The new drug policy has a soft stance with no provisions for direct negotiation by Medicare and resorts to competition for restricting price.

                    Zacks Equity Research

                    AstraZeneca's Two New Cancer Drugs Get Approval in Japan

                    by Zacks Equity Research

                    AstraZeneca gets approval in Japan for two new cancer drugs. These include Lynparza for a breast cancer indication and Imfinzi for an early-stage lung cancer indication.

                      Sweta Killa headshot

                      5 Great Dividend Growth Stocks to Counter Volatility

                      by Sweta Killa

                      Volatility and uncertainty in the stock market has raised the appeal for dividend growth stocks. Here are five picks.

                        Zacks Equity Research

                        Vertex's Shares Rally as a Rival's CF Candidate Disappoints

                        by Zacks Equity Research

                        Vertex Pharmaceuticals' (VRTX) stock rallies on disappointing study results on rival Galapagos' cystic fibrosis candidate. Vertex's third CF drug receives approval in Canada.

                          Zacks Equity Research

                          Gilead's (GILD) CAR T Therapy Gets Positive CHMP Opinion

                          by Zacks Equity Research

                          Gilead (GILD) obtains positive opinion from the CHMP for its MAA for CAR T therapy, axicabtagene ciloleucel, as a treatment for DLBCL and PMBCL.

                            Zacks Equity Research

                            Lilly's (LLY) Taltz Positive in Ankylosing Spondylitis Study

                            by Zacks Equity Research

                            Lilly (LLY) posts positive top-line results from a second phase III study on Taltz for the treatment of Ankylosing Spondylitis (AS).

                              Zacks Equity Research

                              Should Value Investors Consider AbbVie (ABBV) Stock Now?

                              by Zacks Equity Research

                              Let's see if AbbVie Inc. (ABBV) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

                                Nitish Marwah headshot

                                Will a Trade War With China Wreak Havoc in US Healthcare?

                                by Nitish Marwah

                                It is a known fact that Chinese investments breathe life into small and mid-scale healthcare companies in America.

                                  Zacks Equity Research

                                  Amgen Announces Top-Line Data From Remicade Biosimilar Study

                                  by Zacks Equity Research

                                  Amgen (AMGN) presents top-line results from a late-stage study evaluating its biosimilar version of Remicade. Data shows that there was no clinically meaningful difference between the two products.

                                    Zacks Equity Research

                                    AbbVie (ABBV), Calico Extend R&D Deal, to Invest $500M Each

                                    by Zacks Equity Research

                                    AbbVie (ABBV) and Alphabet backed biotech Calico Life Sciences extend their 2014 R&D collaboration by investing another $500 million each to develop candidates to treat age-related diseases.

                                      Zacks Equity Research

                                      AbbVie's (ABBV) Imbruvica sNDA Gets Priority Review From FDA

                                      by Zacks Equity Research

                                      The FDA grants a priority review to AbbVie's (ABBV) lymphoma drug Imbruvica sNDA, for the treatment of Waldenstr??m's macroglobulinemia (WM).

                                        Zacks Equity Research

                                        Gilead's (GILD) Biktarvy Gets EC Nod for HIV- 1 Infection

                                        by Zacks Equity Research

                                        Gilead's (GILD) HIV portfolio gets a further boost with the European Commission's approval of Biktarvy for HIV-1 infection.

                                          Zacks Equity Research

                                          The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, IBM, McDonald's and General Electric

                                          by Zacks Equity Research

                                          The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, IBM, McDonald's and General Electric

                                            Zacks Equity Research

                                            Bristol-Myers Posts Data on Empliciti, China Approves Opdivo

                                            by Zacks Equity Research

                                            Bristol-Myers (BMY) announces positive results on oncology drug Empliciti. The company's blockbuster drug, Opdivo, was also approved in China for lung cancer.

                                              Zacks Equity Research

                                              Abbvie/Roche's Leukemia Drugs Combination Gets FDA Approval

                                              by Zacks Equity Research

                                              AbbVie (ABBV) and Roche's (RHHBY) cancer drugs, Venclexta and Rituxan receive approval for combination use in second-line chronic lymphocytic leukemia.

                                                Indrajit Bandyopadhyay headshot

                                                JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space

                                                by Indrajit Bandyopadhyay

                                                Given the growing interest in JAK-inhibitor based treatments, here's a look at some companies that are looking to change the ways to treat autoimmune diseases.

                                                  Zacks Equity Research

                                                  Gilead Collaborates with Hookipa for HBV and HIV Therapies

                                                  by Zacks Equity Research

                                                  Gilead Sciences (GILD) collaborates with Hookipa Biotech AG for the development of immunization technologies for HBV and HIV diseases.